Beatrice NolanDr. Beatrice Nolan leads the multidisciplinary team at the Comprehensive Care Centre in Children’s Health Ireland at Crumlin, Dublin. Dr. Nolan was appointed as a Consultant Haematologist to St. James’s Hospital in 2001. In 2008 she was then appointed Lead Consultant Haematologist for paediatric haemophilia and allied bleeding disorders at Children’s Health Ireland at Crumlin with a national remit. She is a member of the National Haemophilia Council and the Haemophilia Product Selection and Monitoring Advisory Board.
Beatrice Nolan
Kasia Fennell PhD
Position: Senior Clinical Research Coordinator
Role:
Kasia works with the Haemostasis & Thrombosis Clinical Research team led by Consultant Haematologist Dr. Beatrice Nolan at Children’s Health Ireland at Crumlin.
Róisín Bradley
Position: Clinical Nurse Manager II Children’s Clinical Research Unit
roisin.bradley@olchc.ie
Antje Trainor
Position: Research Nurse
Aileen Molloy
Position: Paediatric Clinical Research Nurse
The list of publications below is automatically derived from MEDLINE/PubMed. As a result, there may be incorrect or missing publications.
| van den Berg HM, Mancuso ME, Königs C, D'Oiron R, Platokouki H, Mikkelsen TS, Motwani J, Nolan B, Santagostino E, European Pediatric Network for Haemophilia Management (PedNet)., 2020 Aug, ITI Treatment is not First-Choice Treatment in Children with Hemophilia A and Low-Responding Inhibitors: Evidence from a PedNet Study. Thromb Haemost, DOI: 10.1055/s-0040-1713097 |
| Pasi KJ, Fischer K, Ragni M, Kulkarni R, Ozelo MC, Mahlangu J, Shapiro A, P'Ng S, Chambost H, Nolan B, Bennett C, Matsushita T, Winding B, Fruebis J, Yuan H, Rudin D, Oldenburg J, 2020 Jun 4, Long-term safety and sustained efficacy for up to 5 years of treatment with recombinant factor IX Fc fusion protein in subjects with haemophilia B: Results from the B-YOND extension study. Haemophilia, DOI: 10.1111/hae.14036 |
| Ahmed SZ, O'Rourke M, Jenkins V, Regan I, Nolan B, 2020 Jun, Progressive increase in FIX level in males with haemophilia B Leyden and c.35G > A mutation in early childhood not related to androgen effect. Br J Haematol, DOI: 10.1111/bjh.16688 |
| Nolan B, Mahlangu J, Pabinger I, Young G, Konkle BA, Barnes C, Nogami K, Santagostino E, Pasi KJ, Khoo L, Winding B, Yuan H, Fruebis J, Rudin D, Oldenburg J, 2020 May, Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: Final results from the ASPIRE extension study. Haemophilia, DOI: 10.1111/hae.13953 |
| Male C, Andersson NG, Rafowicz A, Liesner R, Kurnik K, Fischer K, Platokouki H, Santagostino E, Chambost H, Nolan B, Königs C, Kenet G, Ljung R, van den Berg M, PedNet study group., 2020 Jan 9, Inhibitor incidence in an unselected cohort of previously untreated patients with severe haemophilia B: a PedNet study. Haematologica, DOI: 10.3324/haematol.2019.239160 |
| Carcao M, Escuriola-Ettingshausen C, Santagostino E, Oldenburg J, Liesner R, Nolan B, Bátorová A, Haya S, Young G, Future of Immunotolerance Treatment Group., 2019 Jul, The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab. Haemophilia, DOI: 10.1111/hae.13762 |
| Andersson NG, Auerswald G, Barnes C, Carcao M, Dunn AL, Fijnvandraat K, Hoffmann M, Kavakli K, Kenet G, Kobelt R, Kurnik K, Liesner R, Mäkipernaa A, Manco-Johnson MJ, Mancuso ME, Molinari AC, Nolan B, Perez Garrido R, Petrini P, Platokouki HE, Shapiro AD, Wu R, Ljung R, 2017 Oct, Intracranial haemorrhage in children and adolescents with severe haemophilia A or B - the impact of prophylactic treatment. Br J Haematol, DOI: 10.1111/bjh.14844 |
| Fischer K, Kulkarni R, Nolan B, Mahlangu J, Rangarajan S, Gambino G, Diao L, Ramirez-Santiago A, Pierce GF, Allen G, 2017 Feb, Recombinant factor IX Fc fusion protein in children with haemophilia B (Kids B-LONG): results from a multicentre, non-randomised phase 3 study. Lancet Haematol, DOI: 10.1016/S2352-3026(16)30193-4 |
| Pasi KJ, Fischer K, Ragni M, Nolan B, Perry DJ, Kulkarni R, Ozelo M, Mahlangu J, Shapiro AD, Baker RI, Bennett CM, Barnes C, Oldenburg J, Matsushita T, Yuan H, Ramirez-Santiago A, Pierce GF, Allen G, Mei B, 2017 Feb 28, Long-term safety and efficacy of extended-interval prophylaxis with recombinant factor IX Fc fusion protein (rFIXFc) in subjects with haemophilia B. Thromb Haemost, DOI: 10.1160/TH16-05-0398 |
| Nolan B, Mahlangu J, Perry D, Young G, Liesner R, Konkle B, Rangarajan S, Brown S, Hanabusa H, Pasi KJ, Pabinger I, Jackson S, Cristiano LM, Li X, Pierce GF, Allen G, 2016 Jan, Long-term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia A. Haemophilia, DOI: 10.1111/hae.12766 |
| Young G, Mahlangu J, Kulkarni R, Nolan B, Liesner R, Pasi J, Barnes C, Neelakantan S, Gambino G, Cristiano LM, Pierce GF, Allen G, 2015 Jun, Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A. J Thromb Haemost, DOI: 10.1111/jth.12911 |
| Nijdam A, Kurnik K, Liesner R, Ljung R, Nolan B, Petrini P, Fischer K, PedNet study group., 2015 Jul, How to achieve full prophylaxis in young boys with severe haemophilia A: different regimens and their effect on early bleeding and venous access. Haemophilia, DOI: 10.1111/hae.12613 |
| Nijdam A, Altisent C, Carcao MD, Cid AR, Claeyssens-Donadel S, Kurnik K, Ljung R, Nolan B, Petrini P, Platokouki H, Rafowicz A, Thomas AE, Fischer K, PedNet and CANAL study groups., 2015 Mar, Bleeding before prophylaxis in severe hemophilia: paradigm shift over two decades. Haematologica, DOI: 10.3324/haematol.2014.115709 |
| Nabialek T, Pinnamaneni R, Saleemi MS, Nolan B, Corcoran JD, 2014 Sep, Intra-hepatic haemorrhage and shock during post-natal period, in two brothers with haemophilia. Ir Med J, DOI: 10.3324/haematol.2014.115709 |
| Gouw SC, van den Berg HM, Fischer K, Auerswald G, Carcao M, Chalmers E, Chambost H, Kurnik K, Liesner R, Petrini P, Platokouki H, Altisent C, Oldenburg J, Nolan B, Garrido RP, Mancuso ME, Rafowicz A, Williams M, Clausen N, Middelburg RA, Ljung R, van der Bom JG, PedNet and Research of Determinants of INhibitor development (RODIN) Study Group., 2013 May 16, Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study. Blood, DOI: 10.1182/blood-2012-09-457036 |
| Bacon CL, Singleton E, Brady B, White B, Nolan B, Gilmore RM, Ryan C, Keohane C, Jenkins PV, O'Donnell JS, 2011 May, Low risk of inhibitor formation in haemophilia A patients following en masse switch in treatment to a third generation full length plasma and albumin-free recombinant factor VIII product (ADVATE®). Haemophilia, DOI: 10.1111/j.1365-2516.2010.02430.x |
| Jenkins PV, Egan H, Keenan C, O'Shea E, Smith OP, Nolan B, White B, O'Donnell J, 2008 Jul, Mutation analysis of haemophilia B in the Irish population: increased prevalence caused by founder effect. Haemophilia, DOI: 10.1111/j.1365-2516.2008.01765.x |
| Singleton E, Smith J, Kavanagh M, Nolan B, White B, 2007 Dec, Low risk of inhibitor formation in haemophilia patients after a change in treatment from Chinese hamster ovary cell-produced to baby hamster kidney cell-produced recombinant factor VIII. Thromb Haemost, DOI: 10.1111/j.1365-2516.2008.01765.x |
| Nolan B, Vidler V, Vora A, Makris M, 2003 Jan 18, Unsuspected haemophilia in children with a single swollen joint. BMJ, DOI: 10.1136/bmj.326.7381.151 |
| Nolan B, White B, Smith J, O'Reily C, Fitzpatrick B, Smith OP, 2000 Jun, Desmopressin: therapeutic limitations in children and adults with inherited coagulation disorders. Br J Haematol, DOI: 10.1046/j.1365-2141.2000.02067.x |
| Study Name | Study Title | Study Type | Sponsor | Sponsor Type |
|---|---|---|---|---|
| LoVIC-K | Low Von Willebrand Factor in Ireland Kids Cohort Study | Non-interventional Study | RSCI | Academic - Collaborative Group |
| iPATH | An Irish Personalised Approach to the Treatment of Haemophilia | Non-interventional Study | RCSI, Shire | Industry Supported |
| LTE-15174 | ATLAS-OLE: An Open-label, Long-term Safety and Efficacy Study of Fitusiran in Patients with Hemophilia A or B, with or without Inhibitory Antibodies to Factor VIII or IX | Clinical Trial of IMP | Genzyme Corporation | Industry supported |
| ALN-AT3SC-009 | A Phase 3 study to describe the efficacy and safety of Fitusiran prophylaxis in hemophilia A and B patients previously receiving factor or bypassing agent prophylaxis. | Clinical Trial of IMP | Sanofi Genzyme | Industry supported |
| Elocta-003 ITI Study | A Non-Controlled, Open-Label, Multicenter, Study of Immune Tolerance Induction Performed with rFVIIIFc within a Timeframe of 60 Weeks in Severe Haemophilia A Patients with Inhibitors who have Failed Previous Immune Tolerance Induction Therapies | Clinical Trial of IMP | Sobi (Swedish Orphan Biovitrum AB) | Industry Sponsored |
| PedNET | The European Paediatric Network for Haemophilia Management and the PedNet Haemophilia Registry | Non-Interventional Study | European Paediatric Network for Haemophilia | Academic - Collaborative Group |
| Elocta-004 | A 5-year chart review study of patients with Haemophilia A with Inhibitors treated with rFVIIIFc (Elocta) for Immune Tolerance Induction. | Non-interventional study (Phase IV) | Sobi | Industry Sponsored |
| B-MORE | A 24-month prospective, non-interventional, international, multicentre study to describe the real-world effectiveness and usage of Alprolix in patients with haemophilia B (B-MORE). | Observational | Sobi | Industry Sponsored |
| Study Name | Study Title | Study Type | Sponsor | Sponsor Type |
|---|---|---|---|---|
| 9HB01EXT (BYOND) | Long-Term Safety and Efficacy of rFIXFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia B (B-YOND) | Clinical Trial | Bioverativ | Industry Sponsored |
| Einstein Junior Phase III – 14372 | BAY 59-7939/14372: Multicenter, open-label, active-controlled, randomized study to evaluate the efficacy and safety of an age-and body weight-adjusted rivaroxaban regimen compared to standard of care in children with acute venous thromboembolism | Clinical Trial | Bayer HealthCare AG | Industry Sponsored |
| Leopold | A multi-center Phase III uncontrolled open-label trial to evaluate safety and efficacy of BAY 81-8973 in children with severe haemophilia A under prophylaxis therapy | Clinical Trial | Bayer HealthCare AG | Industry Sponsored |
| Affinity CSL627_3001 | A Phase III Open-label, Multicenter, Extension Study to Assess the Safety and Efficacy of Recombinant Coagulation Factor VIII (rVIII-SinglChain, CSL627) in Subjects with Severe Hemophilia A | Clinical Trial | CSL Behring | Industry Sponsored |
| 8HA02PED (Kids A-LONG) | Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Pediatric Subjects With Hemophilia A | Clinical Trial | Biogen | Industry Sponsored |
| 9HB02PED (Kids B-LONG) | Study of Recombinant Coagulation Factor IX Fc Fusion Protein, BIIB029, in Previously Treated Pediatric Participants With Hemophilia B | Clinical Trial | Biogen | Industry Sponsored |
| 8HA01EXT (ASPIRE) | Long-Term Safety and Efficacy of rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia A | Clinical Trial | Biogen | Industry Sponsored |
| CSLCT-BIO-12-83 | An Open-label, Multi-centre Post-marketing Study to Assess the Efficacy and Safety of Voncento® in Subjects with Von Willebrand Disease | Clinical Trial | CSL Behring | Industry Sponsored |
| Einstein Junior Phase III – 12892 | Phase I: Single-dose pilot study of oral rivaroxaban in pediatric subjects with venous thromboembolism | Clinical Trial | Bayer HealthCare AG | Industry Sponsored |
| Einstein Junior Phase I – 17992 | Single-dose study of oral rivaroxaban dry powder suspension formulation in children treated for thrombosis | Clinical Trial | Bayer HealthCare AG | Industry Sponsored |
| 997HA306 (PUPS A) | An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc) in Untreated Males With Severe Hemophilia A | Clinical Trial | Bioverativ A Sanofi Company | Industry Sponsored |
| 998HB303 (PUPS B) | An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc) in Untreated Males With Severe Hemophilia A | Clinical Trial | Bioverativ A Sanofi Company | Industry Sponsored |
| GAPP | Genotyping and Phenotyping of Platelets | Non-Interventional Study | University of Birmingham | Academic - Collaborative Group |